A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus
Recruiting · NCT07465224 · Interventional (participants receive a specific treatment) · Lead sponsor: Alnylam Pharmaceuticals
View the official record on ClinicalTrials.gov →Interventions studied
ALN-4324Placebo
What this trial is about
The purpose of this study is to evaluate the effect of a single dose of ALN-4324 on whole-body insulin sensitivity in participants with T2DM
Who can take part
Age range
18 Years to 65 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Is an adult patient with a confirmed diagnosis of T2DM
- Has a body mass index (BMI) of ≥23 kg/m\^2 to ≤39.9 kg/m\^2
- Has a hemoglobin A1c (HbA1c) ≥6.5% to \<10.5%
- Is on a stable dose of metformin, sodium-glucose cotransporter 2 inhibitor (SGLT2i), or dipeptidyl peptidase-4 inhibitor (DPP4i)
Exclusion criteria
- Has any clinically significant concomitant disease, medical condition, or abnormal laboratory finding that could compromise participant safety or confound interpretation of study results
- Receiving therapies known to interfere with glucose or insulin metabolism other than current treatment for T2DM or birth control methods
- Note: other protocol defined inclusion/exclusion criteria apply
Where it is running
1 location listed across 1 US state.
- Clinical Trial Site - Chula Vista, California, United States